PLoS ONE (Jan 2008)

Differential screening of phage-ab libraries by oligonucleotide microarray technology.

  • Paolo Monaci,
  • Alessandra Luzzago,
  • Claudia Santini,
  • Alessandra De Pra,
  • Mirko Arcuri,
  • Francesca Magistri,
  • Alessandro Bellini,
  • Helenia Ansuini,
  • Maria Ambrosio,
  • Virginia Ammendola,
  • Maria Giulia Bigotti,
  • Agostino Cirillo,
  • Maurizio Nuzzo,
  • Annamaria Assunta Nasti,
  • Philippe Neuner,
  • Laura Orsatti,
  • Monica Pezzanera,
  • Andrea Sbardellati,
  • Giuseppe Silvestre,
  • Paolo Uva,
  • Valentina Viti,
  • Gaetano Barbato,
  • Stefano Colloca,
  • Anna Demartis,
  • Emanuele De Rinaldis,
  • Saverio Giampaoli,
  • Armin Lahm,
  • Fabio Palombo,
  • Fabio Talamo,
  • Alessandra Vitelli,
  • Alfredo Nicosia,
  • Riccardo Cortese

DOI
https://doi.org/10.1371/journal.pone.0001508
Journal volume & issue
Vol. 3, no. 1
p. e1508

Abstract

Read online

A novel and efficient tagArray technology was developed that allows rapid identification of antibodies which bind to receptors with a specific expression profile, in the absence of biological information. This method is based on the cloning of a specific, short nucleotide sequence (tag) in the phagemid coding for each phage-displayed antibody fragment (phage-Ab) present in a library. In order to set up and validate the method we identified about 10,000 different phage-Abs binding to receptors expressed in their native form on the cell surface (10 k Membranome collection) and tagged each individual phage-Ab. The frequency of each phage-Ab in a given population can at this point be inferred by measuring the frequency of its associated tag sequence through standard DNA hybridization methods. Using tiny amounts of biological samples we identified phage-Abs binding to receptors preferentially expressed on primary tumor cells rather than on cells obtained from matched normal tissues. These antibodies inhibited cell proliferation in vitro and tumor development in vivo, thus representing therapeutic lead candidates.